Skip to main content
. 2019 Aug 17;105(24):1868–1875. doi: 10.1136/heartjnl-2019-315103

Table 3.

PET uptake and baseline characteristics

Total aortic 18F-fluciclatide uptake
All patients Stable cohort Unstable cohort
Continuous variables
 CT calcium score (log10 AU) r=0.37 (0.08–0.60), p=0.01 r=0.62 (0.43–0.81), p<0.001 r=0.20 (−0.28–0.60), p=0.41
 Mean wall thickness (% vessel diameter)* r=0.57 (0.28–0.76), p<0.001 r=0.18 (−0.26–0.56), p=0.43 r=0.69 (0.15–0.91), p=0.02
 Plaque volume (% total volume)* r=0.56 (0.26–0.75), p<0.001 r=0.16 (−0.28–0.55), p=0.47 r=0.68 (0.13–0.90), p=0.02
 Log10 hs-CRP (mg/L) r=0.18 (−0.14–0.46), p=0.28 r=0.32 (−0.07–0.62), p=0.10 r=−0.24 (−0.63–0.24), p=0.06
Categorical variables
 Hypertension (mean TBRmax) 1.33 (1.19–1.39) vs
1.29 (1.20–1.40), p=0.91
1.27 (1.21–1.38) vs
1.33 (1.19–1.38), p=0.90
 Established ischaemic heart disease (mean TBRmax) 1.34 (1.22–1.42) vs
1.25 (1.19–1.35), p=0.15
1.37 (1.37–1.42) vs
1.25 (1.19–1.35), p=0.04
 Hypercholesterolaemia (mean TBRmax) 1.34 (1.21–1.42) vs
1.27 (1.19–1.34), p=0.17
1.36 (1.29–1.41) vs
1.25 (1.19–1.30), p=0.01
 Diabetes mellitus (mean TBRmax) 1.37 (0.32–0.45) vs
1.29 (1.19–1.38), p=0.09
1.37 (1.28–1.58) vs
1.29 (1.19–1.37), p=0.15
 Current smokers (mean TBRmax) 1.32 (1.24–1.49) vs
1.29 (1.19–1.39), p=0.54
N too small

*18F-Fluciclatide uptake assessed in the descending aorta only, to correspond with CT analysis.

AU, arbitrary units; PET, positron emission tomography; TBR, tissue-to-background ratio; hs-CRP, high sensitivity C-reactive protein.